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The intestinal microbiota, which is composed of bacteria, viruses, and micro-eukaryotes, acts as an acces-
sory organ system with distinct functions along the intestinal tract that are critical for health. This review
focuses on how the microbiota drives intestinal disease through alterations in microbial community architec-
ture, disruption of the mucosal barrier, modulation of innate and adaptive immunity, and dysfunction of the
enteric nervous system. Inflammatory bowel disease is used as a model system to understand these micro-
bial-driven pathologies, but the knowledge gained in this space is extended to less-well-studied intestinal
diseases that may also have an important microbial component, including environmental enteropathy and
chronic colitis-associated colorectal cancer.Introduction
The past decade has seen a dramatic rise in metagenomic and
metabolomic studies of inflammatory bowel disease (IBD) and
related inflammatory diseases. The best-understood IBDs
include Crohn’s disease (CD) and ulcerative colitis (UC), which
are chronic inflammatory disorders caused by multiple factors
involving host genetics, the environment, and microbes. As a
result, we are beginning to develop an ecological or commu-
nity-wide understanding of the role of the microbiome in intesti-
nal disease. Recently, these findings have begun to be translated
into a functional mechanistic interpretation of the microbiome in
inflammatory diseases.
In this review, we summarize the latest research on the role of
the intestinal microbiome in inflammatory disease with a focus to-
ward functional and mechanistic studies. We begin by exploring
functional differences that exist along the length of intestinal tract
and how these relate to IBD pathogenesis. We then introduce the
major intestinal vulnerabilities that contribute to IBD and discuss
functional evidence for howmicrobes contribute to either exacer-
bate or prevent onset of disease. Although most studies have
focused on the bacterial component of the microbiome, we also
discuss recent work that explores the impact of viral and micro-
eukaryotic components. IBD can be considered the prototypic
example of the potential for commensal microbes to influence in-
testinal disease, and here IBD is used as a context to interpret the
role of the microbiome in other intestinal inflammatory diseases,
including environmental enteropathy, celiac disease, and colitis-
associated colorectal cancer. Using this integrative approach,
we highlight both recent advances in the field as well as opportu-
nities for novel therapeutic strategies for IBDs.
Functional Differences across the Intestinal Landscape
To appreciate how the microbiota influences chronic inflamma-
tory diseases, especially IBD, it is critical to consider the physio-logical, immunological, and pathological differences along the
intestinal tract. These aspects are often overlooked in studies
concerned with defining the microbial changes that occur in
IBD, yet they will be critical to understand the host pathways
involved in disease initiation. Furthermore, many of the studies
examining microbial changes in IBD have focused on stool sam-
ples, which are incompletely reflective of changes occurring at
proximal sites of the intestine or in mucosal-associated commu-
nities. Functional differences in regions of the intestine are rele-
vant, as CD can affect various areas of both the small and large
intestine, resulting in a segmental pattern of inflammation. In
contrast, UC tends to affect the colon, showing continuous
inflammation. Here we will describe the major functional differ-
ences along the intestine in terms of the composition of the
epithelium, total microbial burdens, and secretion of antimicro-
bial peptides (AMPs) and mucus (Figure 1), focusing on how
these functional differences are relevant to understanding and
elucidating IBD pathogenesis.
Epithelial Layer
Although the small and large intestine have profound functional
differences, they share some structural similarities (Figure 1).
The small intestine is divided into three functionally distinct seg-
ments—the duodenum, jejunum, and ileum—and the function of
the epithelium is regulated by the expression of transcription fac-
tors specific to each segment. For example, GATA4 is expressed
by epithelial cells in the duodenum and jejunum, and reduction of
GATA4 expression causes these cells to absorb bile acid, a func-
tion normally limited to epithelial cells of the ileum (Beuling et al.,
2010). The majority of the digestive and absorptive function of
the intestine occurs in the duodenum and jejunum and is facili-
tated by long villi, as well as microvilli, which contain enzymes
that mediate digestion and transport nutrients. One such brush
border enzyme is intestinal alkaline phosphatase (IAP), which is
highly expressed in the duodenum (Goldberg et al., 2008;Cell Host & Microbe 17, May 13, 2015 ª2015 Elsevier Inc. 577
Figure 1. Differentiating Features of the Small and Large Intestinal Landscape
The small intestine begins after the stomach and is composed of the duodenum, jejunum, and ileum. The ileum joins to the large intestine via the cecum. The large
intestine is composed of the ascending colon, transverse colon, descending colon, and rectum. The small intestine has higher oxygen levels and antimicrobial
peptide (AMP) production, and increased intestinal motility, whereas in the large intestine, themicrobial load is the highest and short-chain fatty acids (SCFAs) are
abundant. The entire length of the intestine is lined by a single layer of epithelial cells. Below these cells is the lamina propria (LP), composed of connective tissue
that provides the blood supply, lymphatic system, and innervation by the submucosal plexus, which are critical to the function of the intestine. Importantly, the LP
houses many immune cells of both the innate and adaptive immune system (not shown). Further enteric enervation occurs in the thin layer of smooth muscle, the
muscularis mucosa, which separates the LP from the underlying submucosa. Below the submucosa is a thickmuscle layer, themuscularis, composed of an inner
circular layer and outer longitudinal layer. Between the two muscle layers is the myenteric plexus, an important component of the enteric nervous system (ENS),
which functions to coordinate intestinal peristalsis. The outermost covering of the intestine is the serosa. At themucosal level, the small intestine has long ‘‘finger-
like’’ villi that project into the lumen, and which are absent in the large intestine. In the small intestine, the crypts contain stem cells, AMP-producing Paneth cells,
and undifferentiated cells; the villi contain the differentiated enterocytes, enteroendocrine cells, and goblet cells. In the small intestine, goblet cells secrete mucus
into the lumen, which has a loose, non-adherent consistency. In the large intestine, the crypts lack Paneth cells and contain only stem cells and undifferentiated
cells; the differentiated cells include enterocytes, enteroendocrine cells, and goblet cells. Here, enterocytes are involved in the production of AMPs and goblet
cells secrete mucus that forms a bilayer structure: the inner and outer mucus layers. Although many of the cell types are shared between the small and large
intestine, the function of these cells varies depending on the intestinal location.
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phate esters, resulting in detoxification of microbial ligands
such as LPS, and is essential to maintain intestinal homeostasis
(Bates et al., 2007; Goldberg et al., 2008). Inflamed mucosal tis-
sue from intestines of patients with CD and UC exhibit reduced
IAP production; this likely occurs through enhanced Toll-like re-
ceptor (TLR) 4 signaling and increased bacterial translocation
into the mucosa (Goldberg et al., 2008; Molna´r et al., 2012). In-
flammatory diseases that affect the small intestine often result
in blunting of villi, leading to malabsorption and malnutrition, as578 Cell Host & Microbe 17, May 13, 2015 ª2015 Elsevier Inc.seen in celiac disease and environmental enteropathy (Dewar
and Ciclitira, 2005; Kelly et al., 2004).
The main functions of the large intestine are the reabsorption
of water and uptake of vitamins (e.g., vitamin K, vitamin B12,
thiamine, riboflavin). The large intestine is also the site of enzy-
matic degradation of indigestible fiber by the microbiota,
producing short-chain fatty acids (SCFAs). SCFAs, including
acetate, propionate, and butyrate, exert a protective effect on
epithelial cells and stimulate fluid absorption (Scheppach,
1994). It is well known that UC leads to changes in microbial
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ment with SCFAs can be clinically beneficial (Harig et al.,
1989). Mechanistically, butyrate is beneficial in UC as it is the
major energy source for the epithelium, induces the differentia-
tion of regulatory T cells (Tregs), and is critical in the resolution
of inflammation by signaling through G protein-coupled receptor
43 (Furusawa et al., 2013; Maslowski et al., 2009).
Microbial Stratification across the Intestine
The microbiota colonizes the entire length of the intestine with
the total number of microbes increasing from the duodenum
to the distal colon, where the microbial load is estimated to be
1012 microbes per gram of feces. There is a widespread belief
that the duodenum and jejunum harbor less than 105 bacteria
per gram of luminal content, and that this number increases in
the ileum to up to 107 bacteria per gram of luminal content,
with further increases in the colon (Berg, 1996; Mowat and
Agace, 2014). A study by Vaishnava et al. (2011) showed that
in the ileum of mice there are 107 mucosal-associated bacteria
compared to 109 fecal bacteria, measured as 16S rRNA gene
copies per cm2 of tissue or feces. Further, this study showed
that a breakdown in the intestinal barrier mediated by a loss
of MyD88 signaling in the epithelium resulted in a full log
increase in mucosal-associated bacteria, with no change in fecal
bacterial counts. Understanding how total bacterial load
changes during IBD may be an interesting aspect of disease
pathogenesis, as increased mucosa-associated bacteria could
drive intestinal inflammation and may explain mixed patient re-
sponses to treatment.
The density of microbial colonization is mainly thought to be
governed by pH, oxygen, and AMP gradients along the length
of the intestine, as well as the speed of transit through the intes-
tine (Figure 1). Reported pH values vary slightly but the trends are
similar: pH is lowest in the duodenum (pH 6.4–6.6), gradually in-
creases toward the terminal ileum (pH 7.3–7.5), decreases in the
cecum (pH 5.7–6.4), and again gradually increases toward the
distal colon (pH 6.6–7.1) (Evans et al., 1988; Fallingborg et al.,
1989). An oxygen gradient exists along the length of the colon,
with levels highest in the duodenum and decreasing to an anaer-
obic environment in the distal colon (He et al., 1999). The slightly
acidic pH and oxygenated environment of the upper small intes-
tine limits microbial colonization to acid- and oxygen-tolerant
bacteria, mainly from the genera Lactobacillus, Streptococcus,
and Veillonella (Frank et al., 2007; Zoetendal et al., 2012). There
is also a radial oxygen gradient in the colon, with oxygen being
produced by the epithelium and consumed by microorganisms
living closest to the mucosa (Albenberg et al., 2014). The chronic
inflammation associated with IBD likely leads to elevated oxygen
levels in the intestine through increased blood flow and immuno-
logical responses such as the release of reactive oxygen spe-
cies, which affect the microbial composition by selecting for
more aerotolerant organisms and disrupting obligate anaerobic
communities (Haberman et al., 2014; Rigottier-Gois, 2013).
A recent study showed that treatment-naive IBD patients at the
time of diagnosis have an altered mucosal-associated bacterial
community that favors the presence of aerotolerant species (Ge-
vers et al., 2014; Haberman et al., 2014). This association of
aerotolerant species could be used as an early diagnostic tool
and suggests a novel therapeutic approach aimed at normalizing
intestinal oxygen levels (Rigottier-Gois, 2013). Similar to theoxygen gradient, intestinal motility also decreases along the
length of the intestinal tract, with the highest velocity docu-
mented in the duodenum and jejunum (Kellow et al., 1986).
Changes in intestinal motility have an important impact on the
severity of IBD (Bickelhaupt et al., 2013; Ohama et al., 2008),
and a recent study showed that intestinal flares in CD are asso-
ciated with a decrease in small intestinal motility and an increase
in inflammatory markers such as C-reactive protein and calpro-
tectin (Bickelhaupt et al., 2013).
Antimicrobial Peptides and the Mucus Layer
The small intestine has numerous Paneth cells located in crypts
(Figure 1), which secrete AMPs including a-defensins, C-type
lectins, lysozyme, and phospholipase A2 (Gallo and Hooper,
2012). AMP secretion is dependent on autophagy, as genetic
disruption of autophagy stalls AMP secretion (Cadwell et al.,
2008). In the large intestine, Paneth cells are absent, but AMP
secretion, including the secretion of b-defensins, C-type lectins,
cathelicidins, galectins, and lipocalin, is mediated by entero-
cytes (Gallo and Hooper, 2012). Interestingly, the microbiome
of the large intestine encodes genes providing resistance to a
specific class of AMPs (Cullen et al., 2015). This resistance con-
fers resilience to the microbial community during inflammation,
when AMP levels are high, allowing faster recovery of the micro-
biota after enteric infection (Cullen et al., 2015).
Intestinal mucus is produced by goblet cells and is mainly
composed of a single, highly O-glycosylated protein, mucin 2
(MUC2), which is secreted into the lumen of the small and large
intestine (Figure 1). Mucus-associated sugars are utilized by in-
testinal microbes, and recent studies show that sensing of
microbial ligands by type 3 innate lymphoid cells stimulates the
addition of fucose to mucus, which in turn supports colonization
of commensal bacteria (Goto et al., 2014; Pickard et al., 2014).
The fucosidase and sialidase activity of certain symbiotic bacte-
ria such asBacteroides thetaiotaomicron to liberatemucosal gly-
cans does not compromise the integrity of themucus layer and is
indeed a common feature of healthy microbiota. However, path-
ogenic bacteria can take advantage of these liberated sugars to
facilitate their expansion (Ng et al., 2013). Further, establishing
immunological tolerance to the intestinal microbiota has been
shown to involve the exposure of dendritic cells to microbe-
MUC2 complexes, recognition of which results in the generation
of tolerogenic signals, dependent on the presence of MUC2, to
specific microbial antigens (Shan et al., 2013). In the small intes-
tine, microbe-triggered secretion of meprin b by enterocytes
causes cleavage of MUC2 from the surface of the epithelium,
preventing the formation of an adherent mucus layer (Schu¨tte
et al., 2014). In contrast, absence of meprin b in the large intes-
tine allows the formation of amucus bilayer (Schu¨tte et al., 2014);
the inner layer is firmly attached to the surface of the epithelium
and is thought to be sterile, while the outer layer is a loose matrix
containing microbes (Johansson et al., 2008). The physiological
requirement for this bilayer structure is likely due to the high
bacterial load of the large intestine, reduced AMP production,
and the slower transit time of fecal matter. IBD patients
have both a thinner inner mucus layer as well as reduced glyco-
sylation of MUC2, with both alterations reducing the barrier
potential of the inner mucus layer (Fyderek et al., 2009; Larsson
et al., 2011). Like AMP secretion, mucus secretion in the large in-
testine is also highly dependent on autophagy, through signalingCell Host & Microbe 17, May 13, 2015 ª2015 Elsevier Inc. 579
Figure 2. Intestinal Vulnerabilities Contributing to IBD
Reduced alpha diversity and a change in the community architecture of the
intestinal microbiota is a key phenotype of IBD and may contribute to disease
initiation. The composition of the intestinal microbiota heavily influences the
metabolic environment of the intestine, and specific metabolites have been
associated with inflammation. Further microbes influence the activity of both
the innate and adaptive arms of the immune system, and these interactions
can initiate disease as well as maintain chronic inflammation. Intestinal
microbes have been shown to produce a variety of neurotransmitters and are
also critical for ENS development and function; these microbial-induced
modifications to the ENS can translate to downstream effects on the mucosal
immune system.
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NLRP6 inflammasome (Patel et al., 2013;Wlodarska et al., 2014).
Autophagy in two types of secretory cells in the intestine,
Paneth cells and goblet cells, is highly relevant to IBD: a CD-
associated risk allele in the autophagy gene ATG16L1 affects
the function of both cell types (Hampe et al., 2007; Rioux et al.,
2007). Genetic risk alleles could also contribute to disease by
influencing composition of themicrobiota; for example, monozy-
gotic twins have a more similar intestinal microbiota than
dizygotic twins (Goodrich et al., 2014), and IBD-related polymor-
phisms are associated with changes in abundance of specific
bacterial taxa (Knights et al., 2014). The degree to which the
functional properties of a host microbiota impact the bi-direc-
tional relationship between host genetics and microbiota
colonization efficacy will be an important area of focus in the
development of microbial therapeutics. For example, fecal mi-
crobiota transplantation (FMT) has proven efficacious in treating
infectious colitis with Clostridium difficile, and as we discuss
below, there has been interest in treating IBD with FMT. How-
ever, it is unknown to what degree an altered genetic back-
ground in IBD patients could affect therapeutic success.
Impact of the Intestinal Microbiome on the
Vulnerabilities of IBD
Metagenomic studies have so far led to a community-level un-
derstanding of recurrent alterations to the microbiome in IBD.
Several groups have refined the resolution of this picture to iden-
tify specific mechanisms by which the intestinal microbiota
affects the course of IBD and related inflammatory diseases.
We attempt to organize these microbial-driven pathologies by580 Cell Host & Microbe 17, May 13, 2015 ª2015 Elsevier Inc.introducing the major vulnerabilities of IBD below (Figure 2). As
the microbiome research field matures to clinical translation in
IBD, these vulnerabilities should serve as the primary targets of
therapeutic intervention.
Microbial Dysbiosis
Recently, using a combined metagenomics- and host-transcrip-
tome-based approach in a large cohort of treatment-naive
pediatric patients with CD, it has been possible to link specific
alterations in the microbiome to host response in clinical dis-
ease. Gevers et al. identified a collection of bacteria that are
differentially abundant in disease and demonstrated that this
set of microbes holds predictive value for clinical outcomes in
CD; the strongest signal was seen from biopsies of the terminal
ileum but, surprisingly, rectal biopsies were nearly as informative
(Gevers et al., 2014). A subset of these patient biopsies were
analyzed by host RNA-seq, revealing a positive correlation be-
tween antimicrobial dual oxidase (DUOX2) expression with the
expansion of Proteobacteria (found to be at increased abun-
dance in CD), while expression of lipoprotein APOA1 was
positively correlated with the abundance of the Firmicutes
(decreased in CD). A regression model including both gene
expression and microbial abundance accurately predicted
remission of disease in this specific cohort of patients (Haber-
man et al., 2014). The signature of increased DUOX2 and
decreased APOA1 expression favored oxidative stress and a
Th1 phenotype and was enriched in patients with severe
mucosal injury (Haberman et al., 2014). Although these specific
associations will need to be confirmed in expanded patient pop-
ulations, this study provides an important framework for future
studies integrating host expression and metagenomics datasets
to make inferences into the interactions between host immune
responses and the microbiome.
The infusion of feces from healthy donors, known as
FMT, has been used for several decades to treat infection with
C. difficile, an endospore-forming, toxin-producing bacterium.
However, the first controlled trial to demonstrate its efficacy
was just recently published; this study showed that C. difficile-
associated diarrhea was resolved after infusion of donor feces
in 15 of 16 patients (van Nood et al., 2013). With this astounding
success, FMT has become the new standard of care for
C. difficile infection. In order to prevent the potential danger of
infection from donor stool, Allen-Vercoe and colleagues, among
other groups, have been designing syntheticmixtures of bacteria
for stool transplant that have been successful in treating
C. difficile infection (Petrof et al., 2013). Most recently, Buffie
et al. (2015) used a workflow involving mouse models, clinical
studies, metagenomic analysis, and mathematical modeling to
identify a single species, the bile acid 7-alpha-dehydroxylating
intestinal bacterium Clostridium scindens, which confers resis-
tance to C. difficile infection and can be used to treat at-risk
individuals.
IBD is objectively more complex than C. difficile infection
because it is the dysbiotic community of bacteria in conjunction
with aberrant mucosal immune responses that drive the patient
toward disease. Several studies evaluating FMT for the treat-
ment of IBD have been published to date, though the sample
sizes are often small. Onemeta-analysis found that 80 of 113 pa-
tients (71%) with IBD showed a reduction or resolution of symp-
toms upon treatment with FMT; however, it is unclear whether
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lenge in utilizing FMT for the treatment of IBD is the difficulty in
predicting which donor strains will be maintained in the host
and at what abundance; therefore, it is crucial to further investi-
gate the factors that are important in species retention by the
recipient and to develop retention prediction software for this
purpose. In addition, the FMT approach for IBD should take
into account both pre-treatment microbiome composition and
immune phenotypes, allowing for the selection of a specific
cocktail of microbes and immunomodulatory drugs to target
the patient’s particular disease state.
Metabolic Effects
Onemechanism by which the microbiome impacts inflammatory
disease is by causing changes to the metabolism of the host.
Host metabolism is deeply intertwined with that of the intestinal
microbiome; for example, humans depend on symbiotic bacteria
for the synthesis of several key vitamins including biotin, folate,
vitamin B5, vitamin B6, riboflavin, and thiamin (Said, 2011). We
also depend on our microbiome for a more complete extraction
of nutrients from our diet beyond what we ourselves can digest.
While the microbiome is an important contributor to metabolism
in the maintenance of health, it can also push our metabolism
toward inflammatory disease.
Hydrogen (H2) and hydrogen sulfide (H2S) production vary
considerably across regions of the gastrointestinal tract and
are involved in immunomodulation. In a study that examined
the microbiome across ten human body habitats (Segata et al.,
2012), the authors found enzymes necessary for the production
and utilization of H2, an anti-inflammatory metabolite (Kajiya
et al., 2009) highly abundant in the oral cavity but nearly absent
from the intestine. H2S is a metabolite produced by microbial
H2 utilization, which at high concentrations can inhibit SCFA pro-
duction and at low concentrations is involved in regulating host
inflammatory responses (Segata et al., 2012). The potential for
production of H2S is particularly high in stool and is strongly posi-
tively associated with the abundance of the pathogenic genera
Treponema and Fusobacterium, suggesting a role in host-cell
toxicity (Segata et al., 2012). A comparison of healthy human vol-
unteers subjected to short term diets composed entirely of either
plant or animal products (David et al., 2014) found that themicro-
biota of the carnivores contained more bile acid-tolerant taxa,
including Alistipes, Bacteroides, and Bilophila, compared to
vegans. High levels of Bilophila wadsworthia, which uses bile
acids as an energy source, leads to increased taurine conjuga-
tion of bile acids and subsequent H2S production. High H2S
levels in turn promote increased levels of proinflammatory Th1
cells and the development of colitis in IL-10/ mice (Devkota
et al., 2012). In pediatric patients with CD, an elemental diet con-
sisting of amino acids, elemental nitrogen, carbohydrates, vita-
mins, minerals, and low fat has been shown to be as efficacious
as corticosteroid therapy (Berni Canani et al., 2006). The
elemental diet causes large changes in gut microbiome compo-
sition and increases microbial diversity (Shiga et al., 2012). As
diet alters the availability of substrates for microbial generation
of potentially harmful metabolites, this finding suggests the
importance of diet in managing IBD.
Another important consideration in inflammatory disease is
the impact of the microbiota on drug metabolism (Haiser et al.,
2013; Maurice et al., 2013). For example, the cardiac glycosidedigoxin causes the intestinal bacterium Eggerthella lenta to upre-
gulate a unique operon encoding glycoside reductases that
use digoxin as an electron acceptor, thus inactivating the drug
(Haiser et al., 2013). The impact of the microbiome on the
metabolism of drugs used to treat inflammatory and other
diseases could help explain why certain drugs are more effective
in some individuals than others and should be more closely
studied.
Barrier Disruption
The separation of the microbiota from the host begins with the
physical barriers: the mucus layer and the epithelium. Compart-
mentalization of the microbiota in the small intestine depends
upon secreted antibacterial proteins, including RegIIIg, a-defen-
sins, and IgA (Gallo and Hooper, 2012). RegIIIg is an antibacterial
lectin that targets Gram-positive bacteria and is under the con-
trol of TLRs (Cash et al., 2006; Duerkop et al., 2009). a-defensins
are small antibacterial peptides that shape the composition of
the luminal intestinal community (Salzman et al., 2003). In mice
lacking an enzyme necessary to process mouse a-defensins, a
large decrease in segmented filamentous bacteria and Th17
cells in the lamina propria was found, although total bacterial
numbers were unchanged (Salzman et al., 2010). IgA is pro-
duced by plasma cells in response to antigens in the luminal
environment, and the secreted form of IgA is transcytosed
across the epithelium to allow binding to luminal bacteria (Mac-
pherson and Uhr, 2004). Recently, Palm and de Zoete et al.
exploited the tendency of IgA to target particularly pathogenic
bacteria to identify a collection of colitogenic bacteria in human
IBD that are heavily coated by IgA (Palm et al., 2014). These col-
lections of bacteria were introduced into germ-free mice, which
subsequently became more susceptible to chemically induced
colitis (Palm et al., 2014). A new study observed striking changes
in fecal IgA levels in wild-type mice that were vertically transmis-
sible and correlated to susceptibility to chemically induced coli-
tis, with lower IgA levels increasing susceptibility to colitis (Moon
et al., 2015). Reduced IgA levels were shown to be due to an
altered microbiome, characterized by the presence of a specific
genus, Sutterella; this altered microbiome resulted in degrada-
tion of the secretory component of IgA (Moon et al., 2015). How-
ever, it remains to be determined which bacterial proteases are
responsible for this degradation of the secretory component,
as well as the relative abundance of these bacterial proteases
in IBD patients.
The expression of antimicrobial peptides in the small intestine
is controlled at least in part by mTOR, which in turn is activated
by the import of the amino acid tryptophan through the ACE2
transport pathway on the luminal surface of epithelial cells (Bro¨er
et al., 2011; Farkas et al., 2006; Hashimoto et al., 2012; Reinisch
et al., 2008). In the mouse, deficiency in Ace2, or a tryptophan-
free diet, results in a drastically altered intestinal microbiome
and increased severity of chemically induced colitis. Transplan-
tation of this altered microbiome to wild-type mice also results in
the aggravation of colitis induced by dextran sodium sulfate
(Hashimoto et al., 2012).
Innate Immunity
The mammalian immune system has co-evolved with its indige-
nous microbiota. It must maintain a rigid balance, on one
hand exhibiting tolerance to symbiotic bacteria while on the
other hand responding to threats from pathogenic bacteria.Cell Host & Microbe 17, May 13, 2015 ª2015 Elsevier Inc. 581
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tory diseases.NOD2, which is responsible for stimulating the im-
mune system in response to bacterial peptidoglycans, was the
first identified susceptibility gene for IBD (Hugot et al., 2001;
Ogura et al., 2001) and is an example of a mechanism by which
inflammatory disease is propagated by an overactive or under-
active response to the symbiotic microbiota.
The microbiota delivers important cues to the host necessary
for the maintenance of homeostasis and intestinal tolerance.
Work in gnotobiotic zebrafish showed that the presence of the
microbiota is essential for recruitment of neutrophils to sites of
injury and found this effect to be mediated by the microbial-
driven production of serum amyloid A (Kanther et al., 2014).
Additionally, microbiota-driven IL-1b production bymyeloid cells
drives the maintenance of colonic regulatory Tregs in a process
that requires production of granulocyte-macrophage colony-
stimulating factor by type 3 innate lymphoid cells, resulting in
Treg homeostasis and the production of regulatory factors
including retinoic acid and IL-10 (Mortha et al., 2014). The pres-
ence of the symbiotic microbiota is necessary for a basal level of
IL-1b production and the consequent homeostasis of several
critical aspects of the immune system.
The intestinal epithelium expresses CD1d, which presents self
and microbial lipid antigens to natural killer T (NKT) cells (Blum-
berg et al., 1991). CD1d is downregulated in inflamed IBD tissue,
and NKT cells are involved in promoting colitis and IBD (Heller
et al., 2002; Olszak et al., 2012). CD1d elicits its protective
effects through the activation of STAT3 and the STAT3-depen-
dent transcription of the regulatory cytokine IL-10, heat shock
protein 110, and CD1d itself and is an important mechanism
by which the immune system maintains tolerance to its micro-
biota. Another recently discovered mechanism by which the
microbiota tempers NKT-cell-mediated inflammation involves
microbial production of sphingolipids, which are ubiquitous
among eukaryotes but present in only a few bacterial genera.
Wieland Brown et al. (2013) purified and solved the structures
of three sphingolipids, also known as glycosylceramides, pro-
duced by a strain of Bacteroides. One of these, a-galactosylcer-
amide, is capable of controlling NKT cell activity. Similarly,
Kasper and colleagues have identified a glycosphingolipid pro-
duced by Bacteroides fragilis that inhibits invariant NKT (iNKT)
cell activity, leading to a reduction in their numbers in the lamina
propria and a decreased severity of disease in a mouse model of
colitis (An et al., 2014). It is important to note that human studies
are required to validate these findings, as very few murine
immune phenotypes have successfully been translated to hu-
man disease.
Adaptive Immunity
The function of the microbiome in adaptive immune cell homeo-
stasis was first uncovered with the discovery that polysaccha-
ride A produced by Bacteroides fragilis restores the Th1/Th2
balance in germ-free mice and protects from colitis by inducing
Tregs (Mazmanian et al., 2005, 2008). Further, colonization of
mice with segmented filamentous bacteria (SFB) in the small in-
testine results in the adherence of SFB to the absorptive cells of
the ileum and those over Peyer’s patches, promoting the pro-
duction of Th17 cells, which are the sole subset of T cells in
the intestine able to detect SFB antigens (Ivanov et al., 2008;
Schnupf et al., 2015; Yang et al., 2014). Since these initial582 Cell Host & Microbe 17, May 13, 2015 ª2015 Elsevier Inc.studies, Honda and colleagues have shown that a group of 46
murine-derived and 17 human-derived Clostridium species can
induce colonic Tregs in mice, resulting in protection from colitis
and allergy (Atarashi et al., 2013). However, there is no effect
on Tregs when any one of these species is used to mono-colo-
nize a germ-free mouse, suggesting that some aspect of the
community-level interactions is required to induce Tregs rather
than any single Clostridium species (Atarashi et al., 2013). The
SCFAs also play an important role in the maintenance of host
adaptive immune function. SFCAs contribute to protection
from inflammation (Maslowski et al., 2009) and induce Treg func-
tion by inhibiting histone deacetylase activity, leading to an in-
crease in acetylation of the Foxp3 gene and increased Foxp3
expression (Arpaia et al., 2013; Atarashi et al., 2013; Furusawa
et al., 2013; Smith et al., 2013b). Future studies should focus
on validating these pathways in human gut mucosa, as the effect
of these specific microbes on the adaptive immune system of
mice will not necessarily translate to human disease.
Enteric Nervous System
The enteric nervous system (ENS) is made up of 200–600 million
neurons that are organized into two plexuses: the myenteric
plexus, which extends the entire length of the gastrointestinal
tract, and the submucosal plexus, only found in the small and
large intestine (Figure 1). The main functions of the ENS include
regulation of intestinal peristalsis, transmucosal fluid flux, local
blood flow, release of intestinal hormones, nutrient absorption,
and interactions with the immune system. The effect of the intes-
tinal microbiota on the ENS is an emerging area of research, and
in-depth characterization of enteric neurons, enteric glial cells
(EGCs), and enteroendocrine cells is required to understand
how microbes communicate with these cells, as well as the
downstream effects on intestinal immunity and physiology, and
how this impacts IBD.
Several molecules with neuroactive function, including
gamma-aminobutyric acid (GABA), tryptamine, indole-3-propi-
onic acid, serotonin, and SCFAs, are produced by intestinal bac-
teria and act on the ENS to modulate intestinal homeostasis
(Table 1). GABA is a well-known enteric neurotransmitter found
at high levels in the myenteric plexus and endocrine cells in the
intestine and is an important modulator of intestinal motility
(Krantis, 2000). Interestingly, GABA signaling in the CNS is linked
to anxiety and depression, which are often associated with IBD.
In mice, ingestion of a Lactobacillus rhamnosus strain results in
altered GABA expression in the brain; however, it is unclear
how GABA signaling in the ENS contributes to this observation
(Bravo et al., 2011). GABA is produced by the host using gluta-
mate as a substrate in a reaction involving L-glutamate decar-
boxylase, and it was recently shown that certain strains of
Lactobacillus and Bifidobacterium also produce GABA in the in-
testine using the same biosynthetic pathway (Barrett et al.,
2012). The production of GABA by the intestinal microbiome is
also affected by diet: in carnivores, catabolic reactions to break
down glutamate are increased (potentially leading to an increase
in intraluminal GABA) whereas herbivores show an increase in
glutamate biosynthesis pathways (Muegge et al., 2011). The
amino acid tryptophan can also be utilized by the intestinal
microbiota, and metabolic byproducts include the production
of tryptamine, serotonin, and indole-3-propionic acid (Wikoff
et al., 2009; Williams et al., 2014). Both tryptamine and serotonin
Table 1. Neuroactive Molecules Produced by Commensal Bacteria in the Intestine
Neuroactive
Molecules Bacterium Catalytic Enzyme/Process Effect Reference
GABA Lactobacillus, Bifidobacterium Glutamate decarboxylase/
Decarboxylation of glutamate
to GABA
Prevents anxiety and
depression
Barrett et al., 2012; Bravo
et al., 2011; Krantis, 2000
Regulates intestinal
motility
Tryptamine Clostridium sprogenes,
Ruminococcus gnavus
Trp decarboxylase/
Decarboxylation of tryptophan
to tryptamine
Induces ion secretion
by IECs
Williams et al., 2014
Induces the release
of serotonin
Indole-3-propionic
acid
Clostridium sporogenes Unknown/Deamination of
tryptophan
Powerful antioxidant Chyan et al., 1999; Wikoff
et al., 2009Production requires
microbiota
Serotonin Unknown Unknown/Metabolite of
tryptophan
Stabilizes mood/anti-
depressant
Fayyaz and Lackner, 2008;
Wikoff et al., 2009
Modulates intestinal
motility
SCFA Bacteroides, Bifidobacterium,
Propionibacterium, Eubacterium,
Lactobacillus, Clostridium
Multiple/Fiber fermentation Energy source Macfarlane and Macfarlane,
2012; Suply et al., 2012Reduce proinflammatory
cytokine production
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motility (Fayyaz and Lackner, 2008; Williams et al., 2014),
whereas the function of indole-3-propionic acid is less under-
stood, but has been found in cerebrospinal fluid and has a neuro-
protective function (Chyan et al., 1999). Further, serotonin
produced by enteroendocrine cells in the intestine has been
shown to contribute to inflammation during chemically induced
colitis inmice, and inhibiting the production ofmucosal serotonin
is sufficient to reduce inflammation (Margolis et al., 2014). How
microbial production of serotonin contributes to intestinal inflam-
mation during IBD is not well described. Microbial-produced
SCFAs have also been shown to enhance enteric neuronal matu-
ration and intestinal motility (Suply et al., 2012).
EGCs, the major cellular component of the ENS, are found in
the mucosa and are essential to ENS function and intestinal
homeostasis. EGCs are closely organized with enteric neuronal
structures, and maintenance of EGC numbers in the mucosa is
dependent on presence of the microbiota (Kabouridis et al.,
2015). Ablation of EGCs results in severe intestinal inflammation
due to a defective intestinal barrier and has been proposed as
one mechanism of CD initiation, as early pathological changes
to EGCs has been reported in patients (Cornet et al., 2001).
EGCs express TLRs 2, 3, and 4, and detection of bacterial
microbe-associated molecular patterns by EGCs has a direct
effect on the barrier function of the intestinal epithelium (Savidge
et al., 2007). Increased susceptibility of TLR2-deficient mice to
chemically induced colitis has recently been shown to result
from alterations in the architecture of the ENS and EGC function
(Brun et al., 2013). Intestinal TLR signaling in response to LPS is
also critical in peristalsis by directing the production of CSF-1 by
enteric neurons. This signaling results in macrophage recruit-
ment to the intestinal muscularis and production of bone
morphogenic protein 2, which acts on enteric neurons that direct
peristalsis (Muller et al., 2014). During antibiotic use, this TLR
signaling was lost, with severe effects on peristalsis. The addi-tion of LPS was able to reverse this defect, but it remains unclear
which cell types propagate the LPS signal to the enteric neurons
(Muller et al., 2014).
IBD and the Neglected Microbes: Micro-Eukaryotes and
Viruses
The intestinal microbiome harbors a micro-eukaryote and viral
community that has been mostly overlooked to date. Here we
highlight recent studies that are beginning to explore the impor-
tance of thesemicrobial communities and their relevance to IBD.
Micro-Eukaryotes
Similar to the bacterial component of the human fecal micro-
biota, the micro-eukaryote community is dependent on geogra-
phy (Parfrey et al., 2014; Yatsunenko et al., 2012). The fecal
microbiome of United States residents, as compared to Mala-
wians, has reduced abundance of fungi and other micro-eukary-
otes both in adult and child populations (Parfrey et al., 2014;
Yatsunenko et al., 2012). This shift in the abundance of intestinal
micro-eukaryotes is likely to be relevant to the hygiene hypothe-
sis, which describes the association of increasingly hygienic
conditions and allergic disease, and may be a factor in the
increased prevalence of IBD in developed countries.
Generally, the abundance of microbes is determined as a per-
centage of total sequencing reads, with the micro-eukaryotes
consisting of 0.01%–0.1%, suggesting low abundance (Parfrey
et al., 2014). However, this methodology likely under-represents
the total micro-eukaryote community, as it does not consider the
microbiome composition in terms of total biomass (with micro-
eukaryotes such as fungi outweighing a typical bacterial cell by
1003). In addition, the identified sequencing reads require
annotated reference sequences that are not well developed
for micro-eukaryotes. Furthermore, no studies have examined
the presence of micro-eukaryotes in the mucosal-associated
portion of the human intestinal microbiota, as all studies have
relied on fecal-derived DNA for sequencing. From a metabolicCell Host & Microbe 17, May 13, 2015 ª2015 Elsevier Inc. 583
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generating a larger small-molecule output compared to bacteria.
A common trend emerging from genomic studies that probe
the micro-eukaryotic population is the widespread prevalence
of the intestinal protist, Blastocystis, in healthy humans around
the world (Alfellani et al., 2013; Nam et al., 2008; Scanlan et al.,
2014). The vast heterogeneity between the nine known Blasto-
cystis subtypes that colonize humans, as well as their low-level
abundance, has led towide variation in reports on the prevalence
of colonization: 5%–56% of individuals in developed countries
and up to 76% in developing countries (Tan, 2008; Turkeltaub
et al., 2015). Of the limited studies that have directly assessed
the possible role of micro-eukaryotes in IBD, Petersen et al.
showed that in Danish cohorts, colonization by micro-eukary-
otes, including Blastocystis and Dientamoeba, is negatively
associated with active UC, suggesting a protective nature of
these protists (Petersen et al., 2013). Although it is unlikely that
a lack of a specific micro-eukaryote is responsible for onset of
IBD, they may have important metabolic functions that reduce
susceptibility to chronic intestinal inflammation.
The human fecal microbiome includes a rich fungal commu-
nity. This observation has also been made for the murine
microbiome, allowing mechanistic insight into the role of fungi
in intestinal health (Iliev et al., 2012; Scupham et al., 2006).
Dectin-1 is a C-type lectin expressed on the surface of neutro-
phils, macrophages, and dendritic cells, which recognizes
b-1,3-glucans found in the cell wall of fungi; ligation of
dectin-1 initiates a Th17-mediated immune response. Iliev
and colleagues (2012) showed that fungi are closely associated
with the mucosa and that fungal-dependent signaling through
dectin-1 is important for maintaining tolerance to the micro-
biota and protection from intestinal inflammation. In line with
this hypothesis, a recent study showed that the association
of mucus with commensal bacteria initiates a tolerogenic signal
to dendritic cells of the small intestine that requires signaling
through dectin-1 (Shan et al., 2013). Further, a mutation in hu-
man dectin-1 (CLEC7A) is associated with medically refractory
UC (Iliev et al., 2012).
Aside from the study by Iliev et al., very little is known regarding
how fungi contribute to host metabolism or inflammatory path-
ways in IBD. Sphingolipid signaling in the host controls many as-
pects of inflammatory diseases, and it is now appreciated that
not all sphingolipids are host derived (Maceyka and Spiegel,
2014). While only a small subset of intestinal bacteria produce
sphingolipids, all fungi contain sphingolipids in their membranes
(Olsen and Jantzen, 2001), with yeast being the best-character-
ized example (Ejsing et al., 2009). One study showed that yeast-
derived sphingolipids can activate host peroxisome proliferator-
activated receptors in the liver (Murakami et al., 2011); however,
an understanding of how these sphingolipids integrate into host
inflammatory pathways is lacking. These studies will require
well-controlled germ-free transfer studies of micro-eukaryote
isolates and better determination of the relative lipidomic profiles
of micro-eukaryotic species and how they interact with the
mucosal immune system of the intestine.
Viruses
A second neglected aspect of the microbiome is the symbiotic
virome. Although viruses have historically been considered
only in the context of single disease-single pathogen relation-584 Cell Host & Microbe 17, May 13, 2015 ª2015 Elsevier Inc.ships, advances in sequencing technology have uncovered the
dramatic size of the virome present in health and disease: it is
estimated that there may be 10-fold more viruses in the human
microbiome than there are bacteria (Mokili et al., 2012), meaning
the virome might outnumber human cells by 100-fold (Breitbart
et al., 2003; Minot et al., 2011, 2012, 2013; Reyes et al., 2010).
The human virome is composed of both eukaryotic viruses as
well as bacteriophages, which directly affect the bacterial micro-
biome composition. For example, Rohwer and colleagues found
that phage capsids express an immunoglobulin-like protein
domain that binds to mucin glycoproteins and may be a source
of non-host-derived innate immunity (Barr et al., 2013). There-
fore, a large ecosystem of viruses exists in the healthy state
‘‘asymptomatically,’’ includingmany viruses that have previously
only been considered in the context of pathogenicity. In recent
years there has been a wealth of data emerging that describes
manifold roles for the virome in inflammatory disease and in
maintaining health. In a recent study, Virgin and colleagues
found that some changes in the composition of the bacterial
community in IBD may be explained by shifts in the bacterio-
phage community (Norman et al., 2015). Using a longitudinal
study design of patients with UC and CD paired with household
healthy controls, the authors described a significant expansion
of the Caudovirales bacteriophages in both CD and UC and a
generalized increase in diversity of the virome concomitant
with a decreased bacterial microbiome diversity (Norman et al.,
2015). Though it is possible that the expanded Caudovirales
may be directly responsible for decreased bacterial diversity, it
is not clear whether the increased abundance of the bacterio-
phage is acquired from the environment or caused by an induc-
tion of prophage by the symbiotic microbiota. Kernbauer et al.
(2014) reported that colonizing germ-free mice with a single
virus, namely murine norovirus, can replace many of the benefi-
cial functions of commensal bacteria. Further, the virus leads to
improvement of several other deficiencies observed in germ-free
mice; these benefits include an increased number of CD3+
T cells, increased Paneth cell function, and higher antibody
levels. The ability of both bacteria and a single virus to remodel
the germ-free intestine suggests that this effect largely occurs
through non-specificmicrobial signals. Furthermore, in response
to dextran sodium sulfate exposure, murine norovirus improves
overall survival and prevents colon-length shortening (Kernbauer
et al., 2014).
Although the interplay between genetics and the microbiome
has been explored largely in terms of the bacterial component,
recent studies also point to the importance of viruses. In mice
with reduced expression of the autophagy gene Atg16l1, Paneth
cells display a number of structural abnormalities and a dysfunc-
tion in granule secretion (Cadwell et al., 2008). However, these
mice appeared normal under germ-free conditions, and intro-
duction of an intestinal norovirus was sufficient to restore the
Paneth cell dysfunction (Cadwell et al., 2010). Similarly, infection
of IL-10-deficient micewith norovirus resulted in epithelial barrier
disruption, illustrating that norovirus provides a colitogenic stim-
ulus that can push the host toward colitis depending on the
composition of the remainder of the intestinal microbiota (Basic
et al., 2014). These examples demonstrate the significance of
viruses in mediating disease phenotypes in genetically suscepti-
ble hosts.
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Diseases
Aside from IBD, there are many other prevalent intestinal inflam-
matory diseases that have not been well explored in terms of the
impact of the microbiome. The knowledge gained from mining
the intestinal microbiome and defining the microbial-driven
pathologies contributing to IBD can now be applied to these
understudied illnesses to unravel their etiology and develop
novel therapeutics.
The Intestinal Microbiome, Inflammation, and Global
Health
Aside from CD and UC, which generally impact individuals living
in high-income countries, distinct IBD-like syndromes exist that
are far more prevalent in low-income countries where poor sani-
tation, hygiene, and malnutrition are widespread. These include
environmental enteropathy (EE), tropical sprue (TS), and immu-
noproliferative small intestinal disease (IPSID). EE and TS are
now recognized to be significant contributors to the sequelae
and persistence of childhood malnutrition worldwide, which is
the leading cause of childhood mortality (Korpe and Petri,
2012). IPSID affects young adults who suffer from chronic inflam-
mation of the small intestine, resulting in lymphoma. However,
despite the wide impact of these diseases, their exact cause(s)
remain unknown. Poor sanitation in low-income countries could
lead to higher exposure to fecal bacteria and increased inci-
dence of enteric infection. The continuous exposure to fecal bac-
teria could result in bacterial overgrowth in the small intestine;
numerous studies have found such overgrowth in children living
with EE symptoms by utilizing hydrogen breath tests (Fagundes
Neto et al., 1994; Khin-Maung-U et al., 1992; dos Reis et al.,
2007) or direct sampling of the small intestinal aspirate (Hey-
worth and Brown, 1975; Omoike and Abiodun, 1989). This
overgrowth of microbes may cause the pathological changes
characteristic of EE, in particular villous blunting, increased in-
testinal permeability, and chronic inflammation that impair the
proximal small intestine and subsequently reduce nutrient ab-
sorption (Lin et al., 2013; Ngure et al., 2014; Weisz et al.,
2012). The transfer of fecal microbiota from severely malnour-
ished children who exhibit EE features was shown to recapitulate
EE disease in the small intestine of germ-free mice, including
villous blunting (Smith et al., 2013a). Eleven strains of IgA-coated
bacteria, including Enterobacteriaceae, were isolated from the
fecal microbiota of these children and were shown to confer
the EE-like phenotype in germ-free mice, suggesting that these
strains may be responsible for disease pathology (Kau et al.,
2015). Alternatively, enteric infection can drastically remodel
the intestine, making it more susceptible to chronic disease
that would be exacerbated with poor sanitary conditions. The
contribution of these microbial changes to the pathophysiology
of EE, TS, and IPSID remain mostly unknown, and similar to
IBD, there is no one pathogen, microbe, gene, or environmental
factor that has been shown to drive disease.
The definition of EE and TS as distinct entities is a source of
debate; however, consensus exists on some important defining
features. EE and TS are similar in that both diseases cause
growth stunting and have similar hallmarks, including chronic
inflammation, malabsorption, villous atrophy, lymphocyte infil-
tration, and increased permeability in the small intestine (Keusch
et al., 2014). However, they differ as EE does not clinically pre-sent with diarrhea whereas TS presents with chronic diarrhea
and is infectious in nature (Korpe and Petri, 2012). An inadequate
diet impacts the immune system, increasing the incidence and
severity of infection in TS, which leads to an altered metabolism
and nutrient loss, exacerbatingmalnutrition (Katona and Katona-
Apte, 2008; Mondal et al., 2012; Schaible and Kaufmann, 2007).
If the enteric infection is cleared in TS, it is not known whether
disease would persist in malnourished children in the form of
post-infectious EE, and hence it is unclear if these two diseases
are independent of each other.
IPSID is a form of small intestinal lymphoma that is mainly seen
in developing countries (Al-Saleem and Al-Mondhiry, 2005). This
type of lymphoma arises from lymphoid infiltration of the
mucosa-associated lymphoid tissue, leading to malabsorption
and protein-losing enteropathy; in advanced stages of disease,
a malignant diffuse large-B cell lymphoma will form (Al-Saleem
and Al-Mondhiry, 2005). From a microbiological perspective,
this unique small intestinal cancer is particularly interesting: early
stages of disease, prior to tumor development, are responsive to
antibiotics, strongly suggesting that the disease may be trig-
gered by microbial infection or microbial dysbiosis. No single
bacterial pathogen has been identified as the cause of IPSID,
although Lecuit et al. (2004) reported that 71% of patients exam-
ined had Campylobacter jejuni associated with the jejunal
mucosa, and a beneficial response to antibiotic treatment was
associated with eradication of C. jejuni. However, changes to
other members of the microbiome have not been explored.
The Intestinal Microbiota, Chronic Inflammation, and
Colorectal Cancer
Several recent studies implicate the intestinal microbiota as an
important player in colorectal cancer (CRC) (Irraza´bal et al.,
2014; Kostic et al., 2013a; Sears and Garrett, 2014). Some of
the alterations observed in the CRC microbiome are also
observed in IBD, and chronic intestinal inflammation is a
major risk factor for the development of CRC. Human studies
comparing bacterial communities in tumors relative to nonin-
volved adjacent colonic tissue have identified Fusobacterium
species as the most strongly enriched taxon at the tumor site
(Castellarin et al., 2012; Kostic et al., 2012; Marchesi et al.,
2011). Fusobacterium is a colonocyte-invading bacterium also
implicated in IBD (Strauss et al., 2011); as IBD is one of the great-
est risk factors for developing CRC, this inflammation-associ-
ated bacteriummay prove to be an important link between these
diseases. More recent studies have associated Fusobacterium
with colorectal adenomas (Kostic et al., 2013b; McCoy et al.,
2013), the precursors to CRC, lending evidence that Fusobacte-
rium is present, if not directly involved, in the tumorigenic
process. The introduction of human colonic isolates of Fusobac-
terium nucleatum to genetically susceptible mice resulted in the
acceleration of intestinal tumorigenesis (Kostic et al., 2013b;
Rubinstein et al., 2013), further lending evidence to a direct
role of Fusobacterium in driving cancer.
Other Intestinal Inflammatory Disease States
Celiac disease, Prevotella-driven disease, and type 1 diabetes
(T1D) have all been associated with particular microbial signa-
tures. Celiac disease is an immune-mediated enteropathy
triggered by dietary wheat gluten in genetically susceptible indi-
viduals. The HLA-DQ genes are themajor genetic determinant of
disease, accounting for 40% of the genetic risk. However, aCell Host & Microbe 17, May 13, 2015 ª2015 Elsevier Inc. 585
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numbers of Staphylococcus and Bacteroides fragilis were also
shown in infants at higher genetic risk for celiac disease and
may contribute to disease progression (Palma et al., 2012). Pre-
votella, an emerging pathobiont implicated in inflammatory and
autoimmune diseases, has been shown to invade colonic crypts,
drive NLRP6-mediated dysbiosis, and exacerbate colitis (Elinav
et al., 2011). A stool-based study of 114 new-onset untreated
rheumatoid arthritis patients and controls identified Prevotella
copri as being strongly associated with disease, and coloniza-
tion of mice with P. copri resulted in more severe chemically
induced colitis (Scher et al., 2013). Interestingly, Pstpip2cmo
mice, which develop spontaneous osteomyelitis, have an intes-
tinal microbiota that is characterized by outgrowth of Prevotella
species (Lukens et al., 2014). A recent prospective longitudinal
study of infants at risk for T1D identified a microbial signature
consisting of a steep drop in community diversity and an expan-
sion of pathobionts including the Rikenellaceae. This signature
correlated with higher fecal b-defensin 2 levels and differentiated
patients whowent on to develop T1D versus non-T1D individuals
one year before clinical diagnosis (Kostic et al., 2015). This study
suggests, as has been shown previously in mice, that a pro-in-
flammatory intestinal microbiota may promote extra-intestinal
inflammatory and autoimmune disorders such as T1D (Markle
et al., 2013; Wen et al., 2008; Yurkovetskiy et al., 2013). Further
longitudinal studies that investigate the microbiome during hu-
man disease are required to clarify whether these changes are
a cause or a consequence of these and other diseases.
Conclusion
Early investigators of IBD searched for a single pathogenic
microbe or pathway responsible for disease; however, recent
studies have proved the inherent flaw in this approach. Relation-
ships between microbes and host processes in the intestine
represent a complex, adaptive system, constantly in flux. There
is incredible inter- and intra-person variability of the microbiome,
with less than 10% of our microbes shared across individuals.
Despite this complexity, there are some fingerprints seen in in-
testinal disease that are shared, such as the observed overall
reduction in microbial diversity and increased abundance of
mucosal-associated aerotolerant bacteria. The reported micro-
bial changes in IBD patients can be considered a microbial
fingerprint that represents an average across an entire cohort
of IBD patients. Although such a fingerprint is useful, what is
needed to enhance our understanding of IBD is stratification of
IBD patients based on specific types of microbial shifts and
the development of a classification system for these microbial
fingerprints. With such a system, it may be possible to under-
stand whether specific microbial fingerprints are associated
with specific patient genetic mutations and whether specific mi-
crobial fingerprints can be used to predict patient response to
current therapeutics. Identification of the relationships between
genetics and microbes are required in order to understand
how these associations can be utilized to logically target specific
treatments for CD and UC, as well as other intestinal disease. For
example, in an IBD patient with a NOD2 polymorphism, which
supports the expansion of Enterobacteriaceae (Knights et al.,
2014), perhaps the ideal synthetic microbial community would
involve beneficial Clostridium strains to enhance Treg function,586 Cell Host & Microbe 17, May 13, 2015 ª2015 Elsevier Inc.in combination with antimicrobials to selectively eliminate strains
within the Enterobacteriaceae family.
IBD can affect multiple areas of the intestinal tract, which
varies greatly along its length with regard to its associated bac-
terial community, and immunological and physiological func-
tions. Therefore, it is likely that the pattern of inflammation and
microbial changes within a patient is critical in understanding
the trigger of disease. This is a largely unexplored area and
would require characterization and stratification of IBD patients
beyond the classical CD and UC classification scheme. Critical
to moving toward patient stratification is the ability to assess
the small intestinal microbiome during disease in patients
without requiring patient bowel preparation (enema or laxative),
as this likely changes the mucosal-associated microbiome and
may mask important microbial phenotypes. This goal could
potentially be achieved with the generation of ingestible nano-
sensors to detect microbes and other physiologically relevant
measures of intestinal health (e.g., oxygen levels, pH, gastroin-
testinal motility). Of interest to the spatial distribution of IBD,
treatment-naive CD patients show significant changes in
mucosal-associated bacteria that are similar in the ileum and
the rectum (Gevers et al., 2014). However, if the microbial
changes are similar in both sites, why does CD occur only in
the ileum and not progress to involve large intestinal inflamma-
tion? If this change in bacterial community structure is driving
disease, what are the key interactions between bacteria in the
ileum and the mucosa that are absent in the rectum?
In addition to the pharmaceutical interest in generating syn-
thetic microbial communities, further understanding of the
metabolites and other compounds produced by our microbiome
(bacterial, viral, and micro-eukaryotic) is another interesting
avenue to develop new therapeutics for IBD and other chronic in-
flammatory conditions. The metabolites produced by members
of our intestinal microbiota have largely been unexplored. How-
ever, the application of metabolomic and metatranscriptomic
approaches to IBD patient cohorts may point to bacterial prod-
ucts that are overabundant or absent in IBD that may have
therapeutic potential. Lastly, there is a great need for hypothe-
sis-based mechanistic studies that utilize what has been learned
through sequencing efforts to focus on understanding the many
uncharacterized microbe-host and microbe-microbe interac-
tions that are critical for maintaining intestinal health. By under-
standing these uncharacterized pathways, we may begin to
understand the interplay of genetics, microbes, and environment
contributing to pathogenesis of intestinal diseases.
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